Core B: Biospecimen Repository and Processing Core

核心B摘要 最近的进展，在治疗转移性黑色素瘤的靶向治疗是非常成功的， 但最终受到肿瘤抗性发展的限制。另一方面，检查点抑制剂是 与持久反应相关，但仅使少数患者受益。所有项目的目标都是 应用是了解机制，并制定战略，以克服抵抗这两个结合 黑色素瘤的靶向治疗和检查点抑制剂免疫治疗。拟议的研究需要一个 高效的生物标本核心，可为研究者提供各种高质量的生物标本。的 PPG生物标本储存和处理核心（BRPC -核心B）的具体目标是：1） 集中执行专业病理学服务，包括生物样本（组织和生物流体）存储， 跟踪、分发和分析; 2）提供良好表征的黑色素瘤组织、细胞系和短期的 来自接受联合治疗并接受BRAF/MEK抑制剂或检查点治疗的患者的培养物 抑制剂和前瞻性开发其他细胞系;和3）开发技术，以更好地表征细胞 从肿瘤微环境内进行更复杂的原位和单细胞水平分析。BRPC 提供黑色素瘤生物学，细胞系开发，病理解释和 所有拟议的研究都要求进行生物储存库管理。

CORE B ABSTRACT Recent advances in the treatment of metastatic melanoma with targeted therapies are highly successful initially but are ultimately limited by the development of tumor resistance. On the other hand, checkpoint inhibitors are associated with durable responses but only benefit a minority of patients. The aims of all of the projects in this application are to understand the mechanisms and develop strategies to overcome resistance to both combined targeted therapies and checkpoint inhibitor immunotherapies in melanoma. The proposed studies require an efficient Biospecimen Core that can provide a variety of high quality biospecimens to the investigators. The specific aims of the Biospecimen Repository and Processing Core (BRPC - Core B) of the PPG are to: 1 ) Centralize performance of specialized pathology services, including biosample (tissue and biofluid) storage, tracking, distribution and analysis; 2) Provide well-characterized melanoma tissues, cell lines and short-term cultures from patients enrolled on combination therapies and treated with BRAF/MEK inhibitors or checkpoint inhibitors and prospectively develop additional cell lines; and 3) Develop techniques to better characterize cells from within the tumor microenvironment for more sophisticated analysis in situ and at the single cell level. BRPC provide the advanced expertise in melanoma biology, cell line development, pathologic interpretation and biorepository management that is required by all proposed studies.